Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dendritic cell-based cancer immunotherapy.

Edgar G Engleman1

  • 1Stanford Medical School Blood Center, Stanford University School of Medicine, Stanford, CA, USA.

Seminars in Oncology
|July 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integration of donor microbiota following FMT correlates with anti-PD-1 response in melanoma.

Nature communications·2026
Same author

Rethinking the origins and functions of adaptive immunity.

Trends in immunology·2026
Same author

A Pan-Cancer Single-Cell Atlas to Evaluate Tumor Identity, Cell Line Concordance, and Dependency Mapping.

bioRxiv : the preprint server for biology·2026
Same author

Macrophage-targeted PEGylated liposomes ameliorate experimental autoimmune encephalomyelitis.

Frontiers in immunology·2026
Same author

Erythropoietin receptor on cDC1s dictates immune tolerance.

Nature·2025
Same author

Author Correction: Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver.

Nature·2025
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Effective cancer vaccines require antigen delivery using dendritic cells (DCs). These potent antigen-presenting cells are crucial for cancer immunotherapy and have shown promise in clinical trials.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Effective cancer vaccines rely on delivering target antigens to elicit an immune response.
  • Dendritic cells (DCs) are potent antigen-processing cells critical for initiating T cell responses.
  • DCs express key molecules for cancer immunotherapy, including MHC class I and II antigens.

Purpose of the Study:

  • To review the role of dendritic cells in cancer immunotherapy.
  • To discuss the activation requirements for dendritic cells.
  • To summarize clinical trials involving antigen-pulsed dendritic cell vaccinations.

Main Methods:

  • Review of existing literature on dendritic cell function and immunotherapy.
  • Analysis of clinical trial data for antigen-pulsed dendritic cell vaccinations.

Related Experiment Videos

  • Discussion of methods for dendritic cell activation and maturation.

    • Main Results:

    • Dendritic cells are essential for sensitizing T cells to antigens.
    • Activation of DCs can be achieved through various methods, including cytokines like granulocyte-macrophage colony-stimulating factor.
    • Clinical trials indicate that antigen-loaded dendritic cell vaccinations are safe and promising for various cancers.

    Conclusions:

    • Dendritic cell-based immunotherapy is a promising strategy for cancer treatment.
    • Further research and clinical trials are warranted to optimize DC vaccination protocols.
    • Dendritic cell vaccines represent a significant advancement in the field of cancer immunotherapy.